drugset / Trial / NCT05928312

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

NCT05928312

Unknown 72 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of fruquintinib combined with chemotherapy as third-line/third-line+ Treatment in advanced metastatic colorectal cancer

Timeline

Start
2023-08-28
Primary completion
2025-06-28
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 4 mg Oral
Subject Irinotecan Small molecule
Subject Oxaliplatin Small molecule

Indications